Both antigens remained co-expressed at the cell level (Figure 2b); as exemplified in Figure 2b, a high level of NGAL-R+/CD38+ CLL cells (>80%) was observed for relapsed patient P44, while the proportion of NGAL-R+/CD38+ CLL cells was low from patient P52 in clinical remission (<10%). Here, SLC22A17 is linked to B-cell chronic lymphocytic leukemia.